Corbion Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
CorbionDie Umsatzerlöse des Unternehmens werden voraussichtlich um 0.2% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 8.7% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 18.6% pro Jahr wachsen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.3% betragen.
Wichtige Informationen
8.7%
Wachstumsrate der Gewinne
18.6%
EPS-Wachstumsrate
Chemicals Gewinnwachstum | 21.9% |
Wachstumsrate der Einnahmen | -0.2% |
Zukünftige Eigenkapitalrendite | 11.3% |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 30 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% Undervalued
Oct 31Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of Debt
Sep 26The Price Is Right For Corbion N.V. (AMS:CRBN)
Jul 18Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value Estimate
Jun 20Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely
May 08Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?
Apr 17Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is Lacking
Jan 20Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Dec 18Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)
Nov 04Corbion (AMS:CRBN) Has A Somewhat Strained Balance Sheet
Sep 13Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)
Aug 04When Should You Buy Corbion N.V. (AMS:CRBN)?
Jul 14Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value Estimate
Jun 04Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden
Apr 21Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56
Mar 10Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?
Feb 22Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business
Jan 26Is Corbion (AMS:CRBN) Using Too Much Debt?
Dec 20Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
Nov 24Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Nov 09Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital Effectively
Oct 08Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden
Sep 19A Look At The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
Aug 23Is It Time To Consider Buying Corbion N.V. (AMS:CRBN)?
Jul 21Investors Could Be Concerned With Corbion's (AMS:CRBN) Returns On Capital
Jul 06Corbion (AMS:CRBN) Is Due To Pay A Dividend Of €0.56
May 20Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
May 17Corbion (AMS:CRBN) Is Due To Pay A Dividend Of €0.56
Apr 28Corbion (AMS:CRBN) Has Announced A Dividend Of €0.56
Apr 07Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business
Mar 26Corbion (AMS:CRBN) Has Affirmed Its Dividend Of €0.56
Feb 27Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?
Feb 27At €37.02, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?
Feb 13A Look At The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
Jan 26Here's Why I Think Corbion (AMS:CRBN) Is An Interesting Stock
Dec 22Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business
Dec 10Is Corbion N.V. (AMS:CRBN) Worth €40.3 Based On Its Intrinsic Value?
Oct 25We Think Corbion (AMS:CRBN) Is Taking Some Risk With Its Debt
Sep 21Corbion (AMS:CRBN) Could Be Struggling To Allocate Capital
Sep 01I Ran A Stock Scan For Earnings Growth And Corbion (AMS:CRBN) Passed With Ease
Aug 17Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business
May 02Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?
Apr 01Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 1,396 | 103 | 65 | 184 | 5 |
12/31/2025 | 1,334 | 86 | 55 | 169 | 5 |
12/31/2024 | 1,298 | 90 | 62 | 135 | 5 |
6/30/2024 | 1,439 | 80 | 66 | 171 | N/A |
3/31/2024 | 1,442 | 77 | 41 | 168 | N/A |
12/31/2023 | 1,444 | 73 | 16 | 165 | N/A |
9/30/2023 | 1,380 | 57 | -61 | 121 | N/A |
6/30/2023 | 1,412 | 54 | -139 | 77 | N/A |
3/31/2023 | 1,435 | 72 | -168 | 58 | N/A |
12/31/2022 | 1,458 | 90 | -197 | 39 | N/A |
9/30/2022 | 1,350 | 76 | -190 | 32 | N/A |
6/30/2022 | 1,243 | 63 | -184 | 25 | N/A |
3/31/2022 | 1,157 | 70 | -155 | 24 | N/A |
12/31/2021 | 1,071 | 78 | -126 | 22 | N/A |
9/30/2021 | 1,040 | 97 | -65 | 59 | N/A |
6/30/2021 | 1,010 | 116 | -4 | 97 | N/A |
3/31/2021 | 998 | 95 | 8 | 103 | N/A |
12/31/2020 | 987 | 73 | 20 | 109 | N/A |
9/30/2020 | 992 | 49 | 20 | 108 | N/A |
6/30/2020 | 997 | 24 | 19 | 107 | N/A |
3/31/2020 | 987 | 25 | 29 | 111 | N/A |
12/31/2019 | 976 | 26 | 38 | 114 | N/A |
9/30/2019 | 953 | 37 | 39 | 109 | N/A |
6/30/2019 | 930 | 48 | 40 | 105 | N/A |
3/31/2019 | 914 | 51 | 40 | 102 | N/A |
12/31/2018 | 897 | 54 | 39 | 100 | N/A |
9/30/2018 | 883 | 61 | 56 | 109 | N/A |
6/30/2018 | 869 | 69 | 74 | 119 | N/A |
3/31/2018 | 880 | 77 | N/A | 118 | N/A |
12/31/2017 | 892 | 85 | N/A | 118 | N/A |
9/30/2017 | 905 | 87 | N/A | 109 | N/A |
6/30/2017 | 918 | 89 | N/A | 101 | N/A |
3/31/2017 | 914 | 95 | N/A | 112 | N/A |
12/31/2016 | 911 | 102 | N/A | 123 | N/A |
9/30/2016 | 917 | 103 | N/A | 124 | N/A |
6/30/2016 | 922 | 104 | N/A | 126 | N/A |
3/31/2016 | 920 | 91 | N/A | 118 | N/A |
12/31/2015 | 918 | 78 | N/A | 110 | N/A |
9/30/2015 | 885 | 45 | N/A | 93 | N/A |
6/30/2015 | 851 | 13 | N/A | 75 | N/A |
3/31/2015 | 811 | -4 | N/A | 71 | N/A |
12/31/2014 | 770 | -21 | N/A | 67 | N/A |
9/30/2014 | 757 | -15 | N/A | 51 | N/A |
6/30/2014 | 744 | -9 | N/A | 34 | N/A |
3/31/2014 | 744 | -3 | N/A | 22 | N/A |
12/31/2013 | 744 | 2 | N/A | 10 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CRBNDas prognostizierte Gewinnwachstum (8.7% pro Jahr) liegt über der Sparquote (1.2%).
Ertrag vs. Markt: CRBNDie Erträge des Unternehmens (8.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Dutch (15.9% pro Jahr).
Hohe Wachstumserträge: CRBNDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: CRBNDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-0.2% pro Jahr).
Hohe Wachstumseinnahmen: CRBNDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-0.2% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: CRBNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.3%).